North Dallas Bank & Trust Co. Invests $1.68 Million in AbbVie Inc. $ABBV

North Dallas Bank & Trust Co. bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,067 shares of the company’s stock, valued at approximately $1,683,000. AbbVie accounts for about 1.3% of North Dallas Bank & Trust Co.’s portfolio, making the stock its 23rd biggest holding.

A number of other hedge funds have also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie during the second quarter valued at about $25,000. TD Capital Management LLC grew its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie in the 2nd quarter valued at approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $39,000. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

AbbVie stock opened at $223.45 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $394.92 billion, a P/E ratio of 169.28, a PEG ratio of 1.21 and a beta of 0.36. The business has a 50-day moving average of $227.25 and a 200-day moving average of $209.76. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the firm earned $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 496.97%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Guggenheim upped their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.